Blog Detail

Ozempic and Wegovy made by Novo Nordisk | Photo Credit: Hollie Adams

Drugmaker Emcure Pharmaceuticals has rolled out its Poviztra, the second brand of Novo Nordisk’s injectable Wegovy, at about 15-20 per cent less than the price of the innovator product, Emcure top management said.

The development increases options for individuals dealing with weight loss and diabetes-induced obesity, and comes a little over a month after Danish healthcare company Novo Nordisk and Emcure announced their Wegovy partnership for India, early November.

Emcure’s product will be available in a once-weekly pen device in five strengths of 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg and a maintenance dosing of 2.4 mg – and the products will be priced starting ₹8,790 per month (4 weekly doses), Emcure said.

Outlining price details, Emcure top-management representatives told businessline - the 0.25 mg dose is priced at ₹8,790; 0.25 and 1 mg dose were pegged at ₹11,200; 1.7 mg was priced at ₹13,000 and 2.4 mg was at ₹15,000. The prices are about 15-20 per cent lower than Wegovy prices, Vikas Thapar, Emcure President (Corporate Development, Strategy and Finance) told businessline.

The last few weeks though, have seen a slew of activity in the weight loss and diabetes segment. Novo Nordisk, on its part, has slashed prices by upto 37 per cent on some doses, besides bringing in its globally popular diabetes drug Ozempic (injectable semaglutide), as well, earlier this month. Novo’s oral version of semaglutide has been available in India for a few years now.

The weight loss and diabetes segment in India has also seen Eli Lilly bring in its product Mounjaro; and the company has partnered with Cipla to bring in Yurpeak, as a second brand of Mounjaro (tirzepatide). The partnerships in the segment come even as some patents on semaglutide expire in certain markets, as early as January 2026.

Several Indian drugmakers, including Dr Reddy’s Laboratories, Cipla, Lupin, Glenmark, Mankind Pharma, among others, are poised to make generic versions of the product, when patents expire on semaglutide.

Emcure too is working on its generic version of semaglutide, but would not be in the first wave of generics, Thapar said.

Referring to global reports of side-effects on loss of vision, among others, Satish Mehta Emcure Chief Executive Officer and Managing Director, said, global trials and reviews of the product showed that the benefits outweighed the risks. And partnering on the innovator product also meant that they would have access to global scientific data on the drug, he added. India is estimated to have nearly 254 million people living with generalised obesity and an additional 351 million living with abdominal obesity, the company said.

Published on December 22, 2025